Bile-Acid-based therapies: Obeticholic acid (an FXR agonist) showed histological improvement of fibrosis in NASH in the phase 3 REGENERATE trial, but it also raised levels of LDL-cholesterol—a known on-target effect of hepatic FXR activation [153]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.